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Our group has conducted two previous studies on the association between vitamin D 
binding protein (DBP) and renal cell carcinoma (RCC), the most common form of kidney cancer, 
finding strong inverse associations. We undertook the current analysis to replicate our findings in 
a different study population that included women and non-smokers. 
We conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial (PLCO). Cases (n=323) were matched 1:1 to controls on age (+/- 1 year), 
race, date of blood collection (+/- 30 days) and sex. We performed conditional logistic regression 
to estimate the odds ratios and 95% confidence intervals for the association between quartiles of 
circulating DBP and risk of RCC.  
We observed a statistically significant positive association between DBP and RCC that 
persisted after adjustment for history of diabetes, history of hypertension, family history of renal 
cancer, body mass index (BMI), and smoking status (mv-adj Q4 vs. Q1 OR=4.1, 95% CI=2.2-
7.8; p-trend <0.0001). These findings were similar when we restricted to cases with at least two 
years of follow-up and no major weight loss, suggesting that our findings are not due to reverse 
causality.  
In the present study, those with higher serum concentrations of DBP were at increased 
risk of RCC, in contrast to previously published findings. Further research is necessary to 
determine the true association between DBP and risk of RCC, and whether different DBP 
phenotypes may have different associations with risk of RCC. 
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 Kidney cancer is estimated to be the 6th most common cancer in men in 2018 (42,680 
cases), and the 10th most common cancer among women (22,660 cases) in the United States. 
About 14,970 (10,010 men and 4,960 women) people are predicted to die from kidney cancer in 
2018 1.  The most common histological subtype is renal cell carcinoma (RCC). Established risk 
factors for this cancer include smoking, obesity, and hypertension, all of which are positively 
associated with risk of RCC 2. In the United States, an estimated 40% of RCC cases are 
attributable to obesity2. Other suggested associations include a positive association with 
acetaminophen use, and a positive association with weight gain independent of obesity 3–5. While 
most RCC is sporadic, approximately 2-4% of kidney cancers can be attributed to hereditary 
factors such as VHL syndrome, and some studies suggest an increased risk for individuals with a 
first degree family history RCC 2. Evidence has shown that higher vitamin D status may be 
protective for some cancers, primarily colorectal 6. However, for cancer at other sites including 
the kidney, studies have demonstrated no association between vitamin D and risk 6–8, with the 
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exception of prostate cancer which is positively associated 9. The association between circulating 
25-hydroxyvitamin D (25(OH)D) and risk of kidney cancer has previously been examined in a 
pooled analysis of data from seven cohorts including the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial (PLCO). This study found no association between 25(OH)D and kidney 
cancer 7. 
The majority of circulating vitamin D is bound to vitamin D binding protein (DBP). In 
addition to its role in vitamin D transport, DBP has several other biologic mechanisms that may 
be relevant to cancer risk. For example, when deglycoslyated by T and B-cell glycosidases, DBP 
is involved in macrophage activation in the form of DBP-macrophage activating factor (DBP-
MAF) 10.  DBP is also involved in apoptosis and angiogenesis10. All of these are related to tumor 
growth and inhibition, and thus could reasonably be related to the association between DBP and 
RCC. Previous studies of the association between DBP and RCC  have been conducted in the 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study 11 and the American Cancer 
Society Cancer Prevention Study-II (CPS-II) Cohort 12, and both found strong inverse 
relationships between serum DBP and risk of RCC, despite there being no association between 
25(OH)D and RCC. CPS-II was a relatively small study (n=87 cases) and the ATBC Study 
(n=262) was conducted only among male smokers in Finland. Thus, the findings require 
replication in larger studies that include women and non-smokers. The present analysis was 
conducted in 323 cases and 323 controls from the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial (PLCO).  
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The PLCO Trial is a large-scale prospective study with the primary goal of determining 
the efficacy of cancer screening on preventing cancer deaths among the named cancers. Details 
of the study have been published previously 13. Briefly, participants aged 55-74 were enrolled 
from 10 centers in the United States between 1993-2001 and were randomized to either an 
intervention or control arm. There were a total of 76,685 men and 78,216 women in the trial, 
with 38,340 and 39,105, respectively, in the screening arm and the rest in the control (non-
screening) arm. The trial period ended in 2006, but active follow up will continue through 2020. 
All participants completed a detailed questionnaire at enrollment including information on 
demographics, diet, cancer risk factors, family history and personal cancer history. Participants 
randomized to the screening arm of the trial provided a non-fasting blood sample at baseline and 
in subsequent screening exams. All samples were shipped overnight to a central repository and 
stored at -700C. The PLCO Trial was approved by the Institutional Review Board of the US 
National Cancer Institute and written informed consent was obtained from all participants. 
We conducted a case-control study nested within the PLCO Trial. All incident cases of 
renal cell carcinoma (ICD code: C64.9) who were diagnosed before February of 2011 and who 
provided a blood sample prior to diagnosis were included. Eligible cases were matched to 
controls 1:1 using incidence density sampling on age (+/- 1 year), race, date of blood collection 
(+/- 30 days) and sex. Our final sample included 323 cases and 323 controls.  
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Serum DBP concentration was measured by the Clinical Support Laboratory, SAIC-
Frederick, Frederick National Laboratory for Cancer Research (Frederick, MD) using the DBP 
polyclonal assay from ALPO Diagnostics (Salem, NH). Each batch contained at least 2 blinded 
quality control duplicates from 2 individuals, one White and one Black. The inter- and intra-
batch coefficients of variation ranged from 7.0 – 11.9% and 0.0 – 16.0%, respectively.  
Statistical Analysis 
 Means and percentages of baseline characteristics by case status and DBP concentration 
were calculated. P-values for the differences between groups were determined using the chi-
square test for categorical and dichotomous variables or the Wilcoxon test for continuous 
variables. We used conditional logistic regression to estimate the odds ratios (OR) and 95% 
confidence intervals (CI) for the association between DBP concentration and renal cell 
carcinoma. Quartile cut points for DBP concentration were determined based on the distribution 
in the controls and were included in the model as indicator variables with the 1st quartile as the 
reference category (Quartiles in μg/mL: <207, 207-<257, 257-<316, ≥316). In sensitivity 
analyses, we also created categories using quartile cut points from previously-published studies 
to facilitate comparison across studies with different distributions of DBP concentration 
(Quartiles in μg/mL; CPS-II: <272, 272-<294, 294-<334, ≥334 11 ATBC: <255, 255-≤323, 323-
<406, ≥406 12).  
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Factors known or hypothesized to be associated with either DBP or renal cell carcinoma 
were evaluated as possible confounders. Factors included in the final model were: history of 
diabetes (yes, no), history of  hypertension (yes, no), family history of renal cancer (yes, no), 
BMI (<25, 25-<30, ≥30 kg/m2), and smoking status (never, current smokers/recent quitter(quit 
<15 years ago), former smokers (quit 15+ years ago) ). All covariate information was reported by 
participants on the baseline questionnaire. Stratified analyses were conducted using 
unconditional logistic regression adjusting for the matching factors.  The main model results 
were unchanged when this approach was used instead of conditional logistic regression, making 
biased estimates unlikely. Analyses were performed stratifying by sex (male, female), smoking 
status (ever smoked, never smoked), number of pack years (above median, below median; for 
smokers only), and weight change since age 50 (gained, lost, or maintained within 5 lbs.). We 
were unable to stratify by race due to a low number of non-whites (n=70) in the dataset. 
However, sensitivity analyses were performed restricting to non-Hispanic whites. We also 
conducted sensitivity analyses excluding cases that occurred within 2 years of blood collection as 
well as those with a large recent weight loss (>40 lbs since age 50) to address the possibility of 
reverse causation. Analyses were conducted stratifying by stage among the cases with available 
stage data (n=116).  
Data availability: The data that support the findings of this study are available from the 
corresponding author upon reasonable request 
Results 
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Distributions of population characteristics by case status and DBP quartile are shown in 
Tables 1 and 2, respectively. Cases were more likely to have a higher BMI, to have smoked, and 
to have a history of diabetes and history of hypertension but were less likely to have a college 
degree (Table 1). Men had lower DBP concentrations than women. Current smokers were more 
likely to have higher DBP concentrations, while former smokers were more likely to have lower 
DBP. Those with a history of diabetes were more likely to be in Q1 than higher quartiles. (Table 
2).  
The association between quartile of DBP and RCC is shown in Table 3.  In models 
conditioned on the matching factors, we observed a positive association between DBP and RCC 
(Q4 vs. Q1 OR=3.9, 95% CI=2.6-7.7; p-trend = <0.0001, Table 3). This association was 
unchanged after multivariable adjustment (Q4 vs. Q1 OR=4.1, 95% CI=2.2-7.8; p-trend = 
<0.0001, Table 3). Sensitivity analyses were performed removing matched pairs where the case 
was diagnosed within 2 years of blood collection or experienced a large weight loss (>40 lbs), 
with no effect on the overall trend (mv-adj Q4 vs. Q1 OR=4.6 CI=2.3-9.1 p-trend=<0.0001, 
Supplemental Table 1). Using DBP cut points from previous studies in the CPS-II 12 and ATBC 
11 cohorts yielded similar results in the PLCO cohort (ATBC cutpoints Q4 vs. Q1 OR=3.7 95% 
CI=1.6-8.7; CPS-II cutpoints Q4 vs. Q1 OR=2.1 95% CI=1.3-3.5; Supplemental Table 2).  
There was a suggestion that the association between DBP and RCC was stronger among 
those with a greater pack-year smoking history (above median of 30: Q4 vs. Q1 OR=6.4 95% 
CI=2.2-19.0; below median: Q4 vs Q1 OR=2.0 95% CI=0.8-5.3; p-interaction=0.09 Table 4). 
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We observed no DBP interaction with sex, BMI, weight change, smoking status, or tumor stage 
at diagnosis (Table 4). Our results were very similar when restricting the analysis to only Whites 
(Q4 vs Q1 OR=4.6 95% CI=2.3-9.1 p-trend=<0.0001). Results were also consistent when 
restricting to only males who had ever smoked in the dataset (Q4 vs Q1 OR=3.4 95% CI=1.5-7.9 
p-trend=0.0004 Supplemental table 3). Although the sample size was small, restricting to male 
current smokers yielded point estimates similar to those observed overall (Q4 vs Q1 OR=3.0 
95% CI=0.2-52.3 p-trend=0.73, Supplemental table 3). 
 
Discussion 
 In this prospective study, we found a strong, statistically significant positive association 
between DBP quartile and RCC that persisted after adjustment for multiple potential 
confounding factors. Our findings were similar when we restricted to cases with at least two 
years of follow up and no major weight loss, suggesting that our findings are not due to reverse 
causality.  
Our findings differ from those reported in the two previous studies on this topic 11 12. 
Both previous studies found strong inverse associations between DBP and RCC. Consistency in 
our findings when using the quartile cut points from these two studies suggest that the difference 
cannot be attributed to different distributions of DBP concentrations across the three study 
populations. If differences in the demographic characteristics of the cohorts were to explain our 
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findings, we would expect the ATBC Study to differ from the other two cohorts, as the ATBC 
cohort was recruited in Finland and comprised only male smokers whereas the CPS-II and PLCO 
cohorts were both recruited from multiple sites in the United States during overlapping calendar 
periods (CPS-II in 1992-1993, and PLCO in 1993-2001). It should be noted that restricting our 
analysis to male smokers did not alter the findings, further suggesting that differences in 
characteristics of the study participants cannot explain these discrepant findings. Additionally, 
CPS-II and PLCO laboratory measurements were performed at the same time at the Clinical 
Support Laboratory, SAIC-Frederick, Frederick National Laboratory for Cancer Research 
(Frederick, MD) using the DBP polyclonal assay from ALPO Diagnostics (Salem, NH). 
Therefore, laboratory error or differences in assay do not explain the different findings in PLCO 
compared to the other two populations.  
 One possible explanation for the different associations across studies is genetics. DBP is 
encoded by the GC gene, which is located on the long arm of chromosome 4. Two SNPs, rs7041 
and rs4588, encode three different variants of the DBP protein, Gc1s, Gc1f, and Gc2 which 
result in six different phenotypes.  Although little work has been done examining the role of 
DBP isoform on cancer risk, one recent study reported that the Gc1f/Gc1f phenotype was 
associated with a reduced risk of cancer at all sites compared to other phenotypes 14. Importantly, 
this phenotype has also been shown to have the highest Gc-MAF activity 15. If the DBP 
phenotypes have different associations with cancer risk, and if the predominant DBP phenotype 
differed across these three studies, this could explain the different results across these three 
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studies. However, it should be noted that the Gc1f/Gc1f phenotype is the least common in 
populations of European descent, which may argue against it driving the inverse findings in the 
ATBC and CPS-II Study populations, which were largely White. Alternatively, these findings 
could be due to chance.  Additional studies are required to elucidate the true association between 
DBP and RCC, and future studies should examine whether DBP phenotype may influence RCC 
risk.  
 This study’s strengths are its relatively large size, the prospective nature of the cohort, 
excellent laboratory reproducibility, and the inclusion of women, non-smokers in the study 
population. Further, we had detailed information on many potential confounding factors for 
which we could adjust in multivariable models. Unfortunately, our study population was largely 
White, possibly limiting our ability to generalize our findings to other racial groups, particularly 
as DBP phenotypes are known to differ meaningfully across racial groups 16. We also lacked 
information on genotype, preventing us from examining the role of DBP phenotype in the DBP-
RCC association.   
 In the present study, those with higher serum concentrations of DBP were at substantially 
increased risk of RCC. Further research is necessary to determine the true association between 
DBP and risk of RCC, and whether different DBP phenotypes may have different associations 
with risk of RCC.  
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Table 1: Selected baseline characteristics [Mean (st. dev.) or percent] for renal cell 









Age (years) 63 (5) 63 (5) matched 
Male 68 68 matched 
Race   matched 
White, non-Hispanic 89.2 89.2  
Black, non-Hispanic 6.2 6.2  
Hispanic 1.6 1.6  
Other 3.1 3.1  
BMI (kg/m2)   <0.0001 
    <25 34.6 22.4  
    25-<30 49.1 41.9  
    ≥ 30 16.4 35.7  
Aspirin use 50.7 51.4 0.88 
Ibuprofen use 26.6 28.6 0.55 
Smoking Status   <0.0001 
Never 48.3 43.7  
Current / quit <15 years  9.6 10.2  
Former quit ≥ 15 years 42.1 46.1  
History of diabetes  4.6 10.5 0.004 
History of hypertension  28.5 45.3 <0.0001 
Completed college 38.1 30.0 0.03 
Family history of any cancer 54.3 51.6 0.47 
Family history of kidney cancer 34.5 43.2 0.86 
* Chi square test for categorical variables, Wilcoxon test for continuous variables, Mcnemar test 
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Table 2: Selected baseline characteristics [Mean (st. dev.) or percent] by quartile of 
vitamin D binding protein in the PLCO Study  






(207 - <257)  
Q3 





Age 63.1 62.8 63.4 62.9 0.52 
Male  72.3 75.7 75.2 50.0 < 0.0001 
Race     0.28 
    White, non-Hispanic 91.1 93.6 85.5 88.9  
    Black, non-Hispanic 4.5 2.1 8.9 7.2  
    Hispanic  2.7 1.4 1.9 0.6  
    Other 1.8 2.9 3.7 3.3  
BMI (kg/m2)     0.62 
    <25 23.4 25.7 30.7 31.1  
    25-<30 51.4 49.3 42.9 41.8  
    ≥30 25.2 25.0 26.4 27.1  
Aspirin use 52.7 51.4 49.1 52.2 0.91 
Ibuprofen use 31.3 28.6 27.2 25.0 0.70 
Smoking status     0.07 
Never smoker 43.8 50.0 43.0 47.8  
Current / quit                      
<15 years 
3.6 7.9 12.2 12.8  
Former quit ≥ 15 years 52.7 42.1 44.8 39.4  
History of Diabetes 12.5 6.4 8.9 3.9 0.04 
History of 
hypertension 
33.0 32.9 39.4 39.4 0.43 
Completed college 37.5 40.0 31.8 30.0 0.20 
Family history of any 
cancer 
52.7 55.7 48.6 56.2 0.42 
Family history of 
kidney cancer 
67.0 39.3 38.8 20.8 0.08 
*chi-square or Fischer’s exact (<5 expected cell count) for categorical variables and Wilcoxon 
test for continuous and dichotomous variables. 
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Table 3: Association between circulating vitamin D binding protein concentration and 
risk of renal cell carcinoma in the PLCO Study 











Cases/Controls 32/80 58/82 132/82 101/79  
OR (95% CI)1 1.0 (ref) 1.9 (1.1 – 3.3) 4.4 (2.6 – 7.7) 3.9 (2.6 – 7.7) <0.0001 
OR (95% CI)2 1.0 (ref) 2.2 (1.2 – 4.0) 4.8 (2.6– 8.7) 4.1 (2.2 – 7.8) <0.0001 
 
1. Conditioned on matching factors. 
2. Conditioned on matching factors. Additionally, adjusted for history of diabetes, history of 
hypertension, family history of renal cancer, BMI, and smoking status.  
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DBP and risk of RCC 
 
Table 4: Association between circulating vitamin D binding protein concentration and 
risk of renal cell carcinoma in the PLCO Study, stratified by selected variables.  
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DBP and risk of RCC 
 
All models adjusted for age, sex, race, history of hypertension, history of diabetes, BMI, and 
smoking status. 
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Vitamin D binding protein (DBP) plays several biological functions of potential 
relevance to cancer risk. However, its role in renal cell carcinoma (RCC) remains 
unclear. This prospective, relatively large nested case-control study revealed a 
statistically significant positive association between DBP and RCC that persisted 
after adjustment for diabetes, hypertension, renal cancer history, body mass index, and 
smoking status. This is a novel finding that runs in opposition to previous cohort studies 
investigating the association between DBP and risk of RCC, calling for further research 
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